Quantitative Multispectral Optoacoustic Tomography
Forthcoming · Germany, France, United Kingdom
Source: EU Funding & Tenders Portal
"Q-MSOT aims to deliver the first handheld optoacoustic tomography system capable of true quantification of tissue chromophores and achieving unprecedented imaging depths (>4 cm) non-invasively in human tissue. Q-MSOT directly addresses two longstanding limitations of optoacoustic imaging: lack of quantification and insufficient penetration. Quantification is enabled by the novel SCOR algorithm, w
- Status
- Prospective
- Sector
- Commercial
- Location
- Germany
- Updated
- 19 Nov 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Quantitative Multispectral Optoacoustic Tomography
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | forthcoming |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | "Q-MSOT aims to deliver the first handheld optoacoustic tomography system capable of true quantification of tissue chromophores and achieving unprecedented imaging depths (>4 cm) non-invasively in human tissue. Q-MSOT directly addresses two longstanding limitations of optoacoustic imaging: lack of quantification and insufficient penetration. Quantification is enabled by the novel SCOR algorithm, which solves the spectral-coloring problem in bio-optics, while deeper penetration is achieved through an optimized ultrasound detector with per-element pre-amplification. Building on results from the EIC Pathfinder project SWOPT (#101046667), Q-MSOT advances the technology from TRL 3 to TRL 5, translating innovative algorithms and hardware into clinical applications, and maturing the business readiness from BRL 3 to BRL 5. The system will enable quantitative readouts of tissue oxygenation and aerobic metabolism in vivo, with significant impact for cancer treatment monitoring and cardiometabolic disease diagnostics. The project includes validation in phantoms, animal models, and pilot human studies, focusing on breast cancer radiotherapy side effect monitoring and muscle bioenergetics. Q-MSOT also features a robust business and IP strategy, aiming for broad clinical adoption, regulatory compliance, and market readiness. The consortium integrates expertise in optoacoustic system design and algorithm development, clinical application, detector development, software, and commercialization, positioning Q-MSOT to set a new standard in quantitative bio-optical imaging and drive European leadership in the field." |
Location
Country | Germany |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Commercial |
Article published date | 2026-09-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
